Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects (Q38815321)

6 September 2017

title

Increasing uncertainty in CNS clinical trials: the role of placebo, nocebo, and Hawthorne effects (English)

1 reference

6 September 2017

0 references

0 references

Fabrizio Benedetti

1

1 reference

6 September 2017

Elisa Carlino

series ordinal

2

1 reference

6 September 2017

Alessandro Piedimonte

series ordinal

3

1 reference

6 September 2017

publication date

19 April 2016

1 reference

6 September 2017

1 reference

6 September 2017

volume

15

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

736-747

1 reference

Placebo and the new physiology of the doctor-patient relationship

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Response expectancy as a determinant of experience and behavior

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebos and painkillers: is mind as real as matter?

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Systematic review of the Hawthorne effect: new concepts are needed to study research participation effects

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Potentiation of placebo analgesia by proglumide

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

The effect of treatment expectation on drug efficacy: imaging the analgesic benefit of the opioid remifentanil

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

For Placebo Effects in Medicine, Seeing Is Believing

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Expectation and dopamine release: mechanism of the placebo effect in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo and opioid analgesia-- imaging a shared neuronal network

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo effects on human mu-opioid activity during pain

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Activation of the opioidergic descending pain control system underlies placebo analgesia.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

1 reference

7 January 2021

Overt versus covert treatment for pain, anxiety, and Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Hidden administration of drugs

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Drugs and placebos: what's the difference?: Understanding the molecular basis of the placebo effect could help clinicians to better use it in clinical practice

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Dissociable influences of opiates and expectations on pain

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Nocebo vs. placebo: the challenges of trial design in analgesia research

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

A systematic review of adverse events in placebo groups of anti-migraine clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Lessons learned from placebo groups in antidepressant trials

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Nocebo is the enemy, not placebo. A meta-analysis of reported side effects after placebo treatment in headaches

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Nocebo in fibromyalgia: meta‐analysis of placebo‐controlled clinical trials and implications for practice

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Adverse events attributable to nocebo in randomized controlled drug trials in fibromyalgia syndrome and painful diabetic peripheral neuropathy: systematic review

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

A meta-analytic approach to estimating nocebo effects in neuropathic pain trials.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo effects: from the neurobiological paradigm to translational implications

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Lacosamide for neuropathic pain and fibromyalgia in adults

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Clinical trial outcome in neuropathic pain: Relationship to study characteristics

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Increasing placebo responses over time in U.S. clinical trials of neuropathic pain

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo response in studies of major depression: variable, substantial, and growing

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Symptom reduction and suicide risk in patients treated with placebo in antidepressant clinical trials: an analysis of the Food and Drug Administration database

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo response in depression: bane of research, boon to therapy.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Listening to Prozac but hearing placebo: A meta-analysis of antidepressant medication

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it?

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Trial design issues and treatment effect modeling in multi‐regional schizophrenia trials

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Nocebo effects in multiple sclerosis trials: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Objective changes in motor function during placebo treatment in PD

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo influences on dyskinesia in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Parkinson's disease gene therapy: success by design meets failure by efficacy

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

AAV2-GAD gene therapy for advanced Parkinson's disease: a double-blind, sham-surgery controlled, randomised trial

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Safety and tolerability of putaminal AADC gene therapy for Parkinson disease

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Safety/feasibility of targeting the substantia nigra with AAV2-neurturin in Parkinson patients

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Effects of perceived treatment on quality of life and medical outcomes in a double-blind placebo surgery trial

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Is acupuncture analgesia an expectancy effect? Preliminary evidence based on participants' perceived assignments in two placebo-controlled trials.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

The impact of patient expectations on outcomes in four randomized controlled trials of acupuncture in patients with chronic pain

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

An extension of control group design

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Hawthorne effect with transient behavioral and biochemical changes in a randomized controlled sleep extension trial of chronically short-sleeping obese adults: implications for the design and interpretation of clinical studies

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Illness by suggestion: expectancy, modeling, and gender in the production of psychosomatic symptoms

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Socially induced placebo analgesia: a comparison of a pre-recorded versus live face-to-face observation

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Seeing facial expressions enhances placebo analgesia.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo analgesia induced by social observational learning

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

The effect of the sex of a model on nocebo hyperalgesia induced by social observational learning

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Nocebo hyperalgesia induced by social observational learning

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Nocebo and placebo modulation of hypobaric hypoxia headache involves the cyclooxygenase-prostaglandins pathway

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Mechanisms Involved in Placebo and Nocebo Responses and Implications for Drug Trials

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

The placebo response in medicine: minimize, maximize or personalize?

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior antidepressant therapy (ADAPT-A Study).

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Genetics and the placebo effect: the placebome

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

The placebo effect: From concepts to genes.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

A link between serotonin-related gene polymorphisms, amygdala activity, and placebo-induced relief from social anxiety.

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Monoamine oxidase a and catechol-o-methyltransferase functional polymorphisms and the placebo response in major depressive disorder

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Catechol-O-methyltransferase val158met polymorphism predicts placebo effect in irritable bowel syndrome

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

FAAH selectively influences placebo effects

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Creating placebo responders and nonresponders in the laboratory: boons and banes

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

The double-blind variable placebo lead-in period: results from two antidepressant clinical trials

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Effectiveness versus efficacy: more than a debate over language

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

A primer on effectiveness and efficacy trials

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Are all placebo effects equal? Placebo pills, sham acupuncture, cue conditioning and their association

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Different Placebos, Different Mechanisms, Different Outcomes: Lessons for Clinical Trials

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

Placebo Effects in Medicine

1 reference

https://api.crossref.org/works/10.1016/S1474-4422(16)50066-1

7 January 2021

10.1016/S1474-4422(16)00066-1

Identifiers

DOI

1 reference

release_pnaep3q36vft5icyfpcre5ric4

6 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/pnaep3q36vft5icyfpcre5ric4

24 November 2022

mapped directly with Wikidata item

1 reference